# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K231752   
B Applicant ARK Diagnostics, Inc.   
C Proprietary and Established Names ARK Hydrocodone Assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DJG</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.3650 -Opiate Test System</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: Hydrocodone   
C Type of Test: Qualitative and semi-quantitative homogeneous immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The ARK Hydrocodone Assay is an immunoassay intended for the qualitative detection and/or semi-quantitative estimation of hydrocodone and its metabolites in human urine at a cutoff of $3 0 0 ~ \mathrm { { n g / m L } }$ . The semi-quantitative mode is for the purpose of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method, such as Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/tandem Mass Spectrometry (LC-MS/MS), or (2) permitting laboratories to establish quality control procedures.

The ARK Hydrocodone Assay provides only a preliminary analytical test result. A more specific alternative chemical method must be used in order to obtain a confirmed positive analytical result. Gas Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/tandem Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug test result, particularly when the preliminary test result is positive.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

# D Special Instrument Requirements:

Beckman Coulter AU 680 chemistry analyzer was used to generate data for this submission.

# IV Device/System Characteristics:

# A Device Description:

The ARK Hydrocodone Assay is a homogeneous enzyme immunoassay (HEIA) technique used for the analysis of Hydrocodone in human urine. The ARK Hydrocodone Assay test system includes separately provided test kits for the ARK Hydrocodone Assay.

The ARK Hydrocodone Assay consists of reagents R1 and R2.

Reagent R1 – Antibody/Substrate solution contains: Rabbit monoclonal antibodies to hydrocodone, glucose-6-phosphate, nicotinamide adenine dinucleotide, bovine serum albumin, sodium azide, and stabilizers.

Reagent R2 – Enzyme solution contains: Hydrocodone derivative labeled with recombinant glucose-6-phosphate dehydrogenase (rG6PDH), bovine serum albumin, buffer, sodium azide and stabilizer.

# B Principle of Operation:

The ARK Hydrocodone Assay is a homogeneous enzyme immunoassay. The assay uses specific antibodies that can detect hydrocodone and its metabolites without any significant cross

reactivity to other opiate compounds. The assay is based on competition between a drug labeled with recombinant glucose-6-phosphate dehydrogenase (rG6PDH) and free drug from the urine sample, for a fixed amount of specific antibody binding sites. In the absence of free drug from the sample, rabbit monoclonal anti-hydrocodone antibody binds to the drug labeled with rG6PDH and causes a decrease in enzyme activity. In the presence of hydrocodone from the specimen, enzyme activity increases and is directly related to the hydrocodone concentration. Endogenous G6PDH does not interfere because the coenzyme NAD functions only with the bacterial enzyme used in the assay. The enzyme activity is determined spectrophotometrically at $3 4 0 \mathrm { n m }$ by measuring the conversion of nicotinamide adenine dinucleotide (NAD) to NADH.

# V Substantial Equivalence Information:

A Predicate Device Name(s): DRI Hydrocodone Assay B Predicate 510(k) Number(s): K150502 C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K231752</td><td rowspan=1 colspan=1>K150502</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>ARK Hydrocodone Assay</td><td rowspan=1 colspan=1>DRI Hydrocodone Assay</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=1>For the detection andestimation of hydrocodone inhuman urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay cutoff</td><td rowspan=1 colspan=1>300 ng/mL of Hydrocodone</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test system type</td><td rowspan=1 colspan=1>Homogenous enzymeimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Rabbit monoclonal</td><td rowspan=1 colspan=1>Mouse monoclonal</td></tr><tr><td rowspan=1 colspan=1>Calibrator Levels</td><td rowspan=1 colspan=1>0, 50, 100, 300, 800 ng/mL</td><td rowspan=1 colspan=1>0, 100, 300, 500, 1000ng/mL</td></tr></table>

# VI Standards/Guidance Documents Referenced:

• CLSI EP12-A2: User Protocol for Evaluation of Qualitative Test Performance. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline - Third Edition.   
• CLSI EP07-A3: Interference Testing in Clinical Chemistry.

• CLSI EP37: Supplemental Tables for Interference Testing in Clinical Chemistry - First Edition.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

A precision study was performed based upon recommendations in the CLSI (EP5‐A3) guideline. Drug free urine samples were spiked with hydrocodone at 0, 75, 150, 225, 300, 375, 450, 525 and $6 0 0 ~ \mathrm { { n g / m L } }$ , representing 0, 25, 50, 75, 100, 125, 150, 175 and $20 \%$ of the device cutoff $( 3 0 0 ~ \mathrm { n g / m L } )$ . Each sample was tested in quadruplicate per run, two runs per day for twenty consecutive days (total $N { = } 1 6 0 /$ level/reagent lot) using 2 reagent lots on the Beckman Coulter AU680 chemistry analyzer. The results are shown below:

Qualitative Precision Results:   

<table><tr><td rowspan=1 colspan=1>HumanUrine(ng/mL)</td><td rowspan=1 colspan=1>Relative% Cutoff</td><td rowspan=1 colspan=1># ofResults</td><td rowspan=1 colspan=1>Lot 1 PrecisionResults</td><td rowspan=1 colspan=1>Lot 2 PrecisionResults</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>160 Negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-75</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>160 Negative</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>-50</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>160 Negative</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>-25</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>160 Negative</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>50 Negative;110 Positive</td><td rowspan=1 colspan=1>69 Negative;91 Positive</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>+25</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>160 Positive</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>+50</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>160 Positive</td></tr><tr><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>+75</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>160 Positive</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>160 Positive</td></tr></table>

Semi-Quantitative Precision Results:

Semi-quantitative Precision Lot 1   

<table><tr><td colspan="1" rowspan="2">HumanUrine(ng/mL)</td><td colspan="1" rowspan="2">Relative%Cutoff</td><td colspan="1" rowspan="2">PrecisionResults</td><td colspan="2" rowspan="1">Repeatability(Within-RunPrecision)</td><td colspan="2" rowspan="1">Between DayPrecision</td><td colspan="2" rowspan="1">Total Precision(Within-LaboratoryPrecision)</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV (%)</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">-100</td><td colspan="1" rowspan="1">160 Negative</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">-75</td><td colspan="1" rowspan="1">160 Negative</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">2.3</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">3.9</td></tr><tr><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">-50</td><td colspan="1" rowspan="1">160 Negative</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1">5.3</td></tr><tr><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">-25</td><td colspan="1" rowspan="1">160 Negative</td><td colspan="1" rowspan="1">7.8</td><td colspan="1" rowspan="1">3.4</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">10.1</td><td colspan="1" rowspan="1">4.4</td></tr><tr><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">Cutoff</td><td colspan="1" rowspan="1">24 Negative;</td><td colspan="1" rowspan="1">11.1</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">7.9</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">14.7</td><td colspan="1" rowspan="1">4.7</td></tr><tr><td colspan="1" rowspan="3">HumanUrine(ng/mL)</td><td colspan="1" rowspan="3">Relative%Cutoff</td><td colspan="1" rowspan="2">PrecisionResults</td><td colspan="2" rowspan="1">Repeatability(Within-RunPrecision</td><td colspan="2" rowspan="1">Between DayPrecision</td><td colspan="2" rowspan="1">Total Precision(Within-LaboratoryPrecision)</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV (%)</td></tr><tr><td colspan="1" rowspan="1">136 Positive</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">375</td><td colspan="1" rowspan="1">+25</td><td colspan="1" rowspan="1">160 Positive</td><td colspan="1" rowspan="1">14.3</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">11.2</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">18.8</td><td colspan="1" rowspan="1">4.8</td></tr><tr><td colspan="1" rowspan="1">450</td><td colspan="1" rowspan="1">+50</td><td colspan="1" rowspan="1">160 Positive</td><td colspan="1" rowspan="1">20.9</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">16.5</td><td colspan="1" rowspan="1">3.6</td><td colspan="1" rowspan="1">27.9</td><td colspan="1" rowspan="1">6.1</td></tr><tr><td colspan="1" rowspan="1">525</td><td colspan="1" rowspan="1">+75</td><td colspan="1" rowspan="1">160 Positive</td><td colspan="1" rowspan="1">31.7</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">24.2</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">43.6</td><td colspan="1" rowspan="1">8.1</td></tr><tr><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">+100</td><td colspan="1" rowspan="1">160 Positive</td><td colspan="1" rowspan="1">50.4</td><td colspan="1" rowspan="1">8.1</td><td colspan="1" rowspan="1">38.3</td><td colspan="1" rowspan="1">6.2</td><td colspan="1" rowspan="1">61.4</td><td colspan="1" rowspan="1">9.9</td></tr></table>

Semi-quantitative Precision Lot 2   

<table><tr><td rowspan=2 colspan=1>HumanUrine(ng/mL)</td><td rowspan=2 colspan=1>Relative%Cutoff</td><td rowspan=2 colspan=1>PrecisionResults</td><td rowspan=1 colspan=2>Repeatability(Within-RunPrecision)</td><td rowspan=1 colspan=2>Between DayPrecision</td><td rowspan=1 colspan=2>Total Precision(Within-LaboratoryPrecision)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-75</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>-50</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>-25</td><td rowspan=1 colspan=1>160 Negative</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>35 Negative;125 Positive</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>+25</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>16.7</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>+50</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>26.3</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>+75</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>35.0</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>+100</td><td rowspan=1 colspan=1>160 Positive</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>7.5</td></tr></table>

# 2. Linearity/Recovery:

Linearity study in the semi-quantitative mode was conducted by spiking a drug free urine pool with hydrocodone (serial dilutions of a high concentration hydrocodone in negative urine pool) to achieve concentrations ranging from $0 \mathrm { n g / m L }$ to $8 0 0 ~ \mathrm { { n g / m L } }$ , and testing each level on two reagent lots in replicates of five on the Beckman Coulter AU680 clinical chemistry analyzer. The results from a representative lot are summarized below:

<table><tr><td rowspan=1 colspan=1>Expected Value(ng/mL)</td><td rowspan=1 colspan=1>Observed Value(ng/mL)</td><td rowspan=1 colspan=1>Recovery (%)</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>79.4</td><td rowspan=1 colspan=1>99.3</td></tr><tr><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>151.1</td><td rowspan=1 colspan=1>94.5</td></tr><tr><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>246.8</td><td rowspan=1 colspan=1>102.9</td></tr><tr><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>321.7</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>385.8</td><td rowspan=1 colspan=1>96.5</td></tr><tr><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>472.3</td><td rowspan=1 colspan=1>98.4</td></tr><tr><td rowspan=1 colspan=1>560</td><td rowspan=1 colspan=1>537.4</td><td rowspan=1 colspan=1>96.0</td></tr><tr><td rowspan=1 colspan=1>640</td><td rowspan=1 colspan=1>606.4</td><td rowspan=1 colspan=1>94.7</td></tr><tr><td rowspan=1 colspan=1>720</td><td rowspan=1 colspan=1>620.6</td><td rowspan=1 colspan=1>86.2</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>737.5</td><td rowspan=1 colspan=1>92.2</td></tr></table>

# 3. Analytical Specificity/Interference:

# Specificity:

An analytical specificity study to evaluate interference from non-structurally and structurally related compounds was performed in the qualitative and semi-quantitative mode. The study design and results are described below. Results were the same for each mode (qualitative and semi-quantitative modes).

# Hydrocodone and its Metabolites

The following metabolites of hydrocodone were approximately equivalent to the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff at the concentrations tested with the ARK Hydrocodone Assay. Dihydrocodeine tested negative at $1 0 0 , 0 0 0 ~ \mathrm { n g / m L }$ . Immunoassay reactivity for hydrocodone and hydromorphone were equivalent.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationApproximatelyEquivalent tothe Cutoff (ng/mL)</td><td rowspan=1 colspan=1>PercentCross-reactivity(%)</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>292</td><td rowspan=1 colspan=1>102.8</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>299</td><td rowspan=1 colspan=1>100.4</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone-3β-Glucuronide</td><td rowspan=1 colspan=1>45,439</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>Norhydrocodone</td><td rowspan=1 colspan=1>2,277</td><td rowspan=1 colspan=1>13.2</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.3</td></tr></table>

# Structurally Related Compounds and Other Opiates

To evaluate potential cross-reactivity for the ARK Hydrocodone assay, structurally similar compounds were spiked into drug free urine at concentrations that will yield a result that is equivalent to the $3 0 0 \mathrm { n g / m L }$ cutoff. For compounds that did not produce a positive result, the highest concentration tested was used to calculate percent cross-reactivity. The percent cross-reactivity is presented in the table below.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationTested (ng/mL)</td><td rowspan=1 colspan=1>Result N=3(POS/NEG)</td><td rowspan=1 colspan=1>Percent Cross-reactivity(%)</td></tr><tr><td rowspan=1 colspan=1>6-Acetyl morphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine-3β-D-glucuronide</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.6</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Codeine-6β-D-glucuronide</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>250,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1</td></tr><tr><td rowspan=1 colspan=1>EDDP</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>EMDP</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Ethyl morphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Fentanyl</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Heroin</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>K0.3</td></tr><tr><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Meperidine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Methadone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Morphine-3β-D-glucuronide</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Morphine-6β-D-glucuronide</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Nalbuphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Naloxegol</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Normorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Noroxycodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Nortilidine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>K0.3</td></tr><tr><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone-3β-D-glucuronide</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>K0.6</td></tr><tr><td rowspan=1 colspan=1>Pentazocine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Tapentadol</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>K0.3</td></tr><tr><td rowspan=1 colspan=1>Thebaine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Tilidine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.3</td></tr><tr><td rowspan=1 colspan=1>Tramadol</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>K0.3</td></tr></table>

Potential interference from non-structurally related drugs and metabolites was evaluated in the qualitative and semi-quantitative modes, by spiking these compounds at high concentrations in drug free urine spiked with hydrocodone at $\pm 2 5 \%$ of the cutoff (225 and $3 7 5 ~ \mathrm { { n g / m L } }$ ).

<table><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">ConcentrationTested(ng/mL)</td><td colspan="1" rowspan="1">Result N=3(POS/NEG)</td></tr><tr><td colspan="1" rowspan="1">(+)-MDA</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">11-hydroxy-delta-9-THC</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">11-nor-9 carboxy THC</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">1R,2S(-)-Ephedrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">1S,2R(+)-Ephedrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">4-Bromo-2,5,Dimethoxyphenethylamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">7-Aminoclonazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic acid</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Alprazolam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Amphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Atorvastatin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Benzylpiperazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Bupropion</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Butabarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Canagliflozin</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Cannabidiol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Cannabinol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Carisoprodol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Cimetidine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Clobazam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Clopidogrel</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Cocaine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Cotinine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Cyclobenzaprine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Doxepin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ecgonine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ephedrine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Fluphenazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Lamotrigine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Lidocaine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">LSD</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">MDMA</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Meprobamate</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Metformin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Metronidazole</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Norpseudoephedrine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Nortriptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Omeprazole</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ondansetron</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Phenobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Phentermine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Phenylephrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Phenylpropanolamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">PMA</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Propranolol</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Protriptyline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">R,R(-)-Pseudoephedrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ranitidine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Ritalinic Acid</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">S(+)-Methamphetamine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">S,S(+)-Pseudoephedrine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Salicylic Acid</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Secobarbital</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Sertraline</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Temazepam</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Thioridazine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Trazodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Triazolam</td><td colspan="1" rowspan="1">250,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Trimipramine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Venlafaxine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr><tr><td colspan="1" rowspan="1">Zolpidem</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">NEG</td></tr></table>

# Endogenous Compounds

Potential interference from endogenous compounds commonly found in urine was evaluated in the qualitative and semi-quantitative modes, by spiking these compounds into drug free urine containing hydrocodone at $\pm 2 5 \%$ of the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff (225 and $3 7 5 ~ \mathrm { { n g / m L } }$ ).

<table><tr><td rowspan=1 colspan=1>Interfering Substances</td><td rowspan=1 colspan=1>ConcentrationTested (mg/dL)</td><td rowspan=1 colspan=1>225 ng/mLHydrocodoneN=3(POS/NEG)</td><td rowspan=1 colspan=1>375 ng/mLHydrocodoneN=3(POS/NEG)</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Acetyl Salicylic Acid</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Human γ- Globulin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>NaCl</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Oxalic Acid</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>POS</td></tr></table>

# pH and Specific Gravity:

For potential interference from the $\mathsf { p H }$ of urine, device performance in the qualitative and semi-quantitative modes was tested using a range of urine $\mathsf { p H }$ values (3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0,10.0 and 11.0). All test samples were prepared in drug free urine containing hydrocodone at $\pm 2 5 \%$ of the cutoff $( 2 2 5 ~ \mathrm { n g / m L }$ and $3 7 5 ~ \mathrm { { n g / m L } }$ hydrocodone

concentrations). No positive or negative interference was observed at urine pH values ranging from 3.0 to 11.0 for each test mode.

For potential interference from the specific gravity of urine, device performance in the qualitative and semi-quantitative modes was tested using a range of urine specific gravity values (1.000, 1.0021, 1.0043, 1.0179, 1.0187, 1.0262, 1.0303). All test samples were prepared in drug free urine containing hydrocodone at $\pm 2 5 \%$ of the cutoff $( 2 2 5 ~ \mathrm { n g / m L }$ and $3 7 5 ~ \mathrm { { n g / m L } }$ hydrocodone concentrations). No positive or negative interference was observed at urine specific gravity values ranging from 1.000 to 1.0303 for each test mode.

# Boric Acid:

One percent $( 1 \% )$ w/v of boric acid was tested in the presence of hydrocodone at $2 2 5 ~ \mathrm { { n g / m L } }$ and $3 7 5 ~ \mathrm { { n g / m L } }$ .

<table><tr><td>Compound</td><td>Concentration Tested</td><td>225 ng/mL Hydrocodone N=3 (POS/NEG)</td><td>375 ng/mL Hydrocodone N=3 (POS/NEG)</td></tr><tr><td>Boric Acid</td><td>1% w/v</td><td>NEG</td><td>NEG</td></tr></table>

The following limitations statement is included in the Instructions for Use/Package Insert:

“Do not use Boric Acid as a preservative.”

4. Assay Reportable Range: See the linearity section, VII.A.2., above.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Traceability: ARK Hydrocodone Assay is traceable to a commercially available standard.

6. Detection Limit: Not applicable.

7. Assay Cut-Off:

Characterization of how the device performs analytically around the claimed cutoff concentration of $3 0 0 ~ \mathrm { { n g / m L } }$ hydrocodone is described in the precision section, VII.A.1., above.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

A total of 226 unaltered urine samples from pain management laboratories were analyzed by two lots of the candidate device in the qualitative and semi-quantitative modes on the Beckman Coulter AU680 clinical chemistry analyzer and the comparative mass spectrometry based quantitative method (LC-MS/MS). LC-MS/MS and immunoassay qualitative results are based on a $3 0 0 \mathrm { n g / m L }$ cutoff. The results from the study in the two modes are summarized below:

Lot 1 Qualitative method comparison with LC-MS/MS as reference method   

<table><tr><td rowspan=1 colspan=1>ARKHydrocodoneAssay Results</td><td rowspan=1 colspan=1>&lt;50% ofcutoffconcentrationby LC-MS/MS</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below thecutoff andthe cutoffconcentrationby LC-MS/MS)(150-299ng/mL)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above the cutoffconcentrationby LC-MS/MS)(300-450ng/mL)</td><td rowspan=1 colspan=1>High Positive(Greater than50% above thecutoffconcentrationby LC-MS/MS)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>66</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>0</td></tr></table>

Lot 2 Qualitative method comparison with LC-MS/MS as reference method   

<table><tr><td rowspan=1 colspan=1>ARKHydrocodoneAssay Lot 2Results</td><td rowspan=1 colspan=1>&lt;50% of cutoffconcentrationby LC-MS/MS(&lt;150 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffandthe cutoffconcentration byLC-MS/MS)(150-299 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above thecutoffconcentrationby LC-MS/MS)(300-450ng/mL)</td><td rowspan=1 colspan=1>High Positive(Greater than50% above thecutoffconcentration byLC-MS/MS)(&gt;450 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>66</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>0</td></tr></table>

Lot 1 Semi-quantitative method comparison with LC-MS/MS as reference method   

<table><tr><td rowspan=1 colspan=1>ARKHydrocodoneAssay Lot 1Results</td><td rowspan=1 colspan=1>&lt;50% of cutoffconcentrationby LC-MS/MS(&lt;150 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffandthe cutoffconcentration byLC-MS/MS)(150-299 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and 50%above thecutoffconcentrationby LC-MS/MS) (300-450 ng/mL)</td><td rowspan=1 colspan=1>High Positive(Greater than50% above thecutoffconcentration byLC-MS/MS)(&gt;450 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>66</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>0</td></tr></table>

Lot 2 Semi-quantitative method comparison with LC-MS/MS as reference method   

<table><tr><td rowspan=1 colspan=1>ARKHydrocodoneAssay Lot 2Results</td><td rowspan=1 colspan=1>&lt;50% ofcutoffconcentrationby LC-MS/MS(&lt;150 ng/mL)</td><td rowspan=1 colspan=1>Near CutoffNegative(Between 50%below the cutoffandthe cutoffconcentration byLC-MS/MS)(150-299ng/mL)</td><td rowspan=1 colspan=1>Near CutoffPositive(Between thecutoff and50% above thecutoffconcentrationby LC-MS/MS) (300-450 ng/mL)</td><td rowspan=1 colspan=1>High Positive(Greater than50% above thecutoffconcentration byLC-MS/MS)(&gt;450 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>66</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

# \*Discordant Results

<table><tr><td colspan="1" rowspan="2">Sample#</td><td colspan="1" rowspan="2">ARKLot 1Qual.(POS/NEG)</td><td colspan="1" rowspan="2">ARKLot 2Qual.(POS/NEG)</td><td colspan="2" rowspan="1">LC-MS/MS (ng/mL)</td><td colspan="1" rowspan="1">ARKLot 1Semi-quant.(ng/mL)</td><td colspan="1" rowspan="1">ARKLot 2Semi-quant.(ng/mL)</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">287.8</td><td colspan="1" rowspan="1">210.0</td><td colspan="1" rowspan="1">476.0</td><td colspan="1" rowspan="1">664.3</td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">226.9</td><td colspan="1" rowspan="1">150.5</td><td colspan="1" rowspan="1">390.0</td><td colspan="1" rowspan="1">415.0</td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">156.0</td><td colspan="1" rowspan="1">174.7</td><td colspan="1" rowspan="1">335.2</td><td colspan="1" rowspan="1">338.6</td></tr><tr><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">1317.7</td><td colspan="1" rowspan="1">387.7</td><td colspan="1" rowspan="1">467.9</td></tr><tr><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="1">NEG</td><td colspan="1" rowspan="1">306.5</td><td colspan="1" rowspan="1">22.4</td><td colspan="1" rowspan="1">277.6</td><td colspan="1" rowspan="1">307.0</td></tr><tr><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">162.0</td><td colspan="1" rowspan="1">52.4</td><td colspan="1" rowspan="1">316.1</td><td colspan="1" rowspan="1">312.8</td></tr><tr><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">200.5</td><td colspan="1" rowspan="1">61.7</td><td colspan="1" rowspan="1">358.4</td><td colspan="1" rowspan="1">347.9</td></tr><tr><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">174.4</td><td colspan="1" rowspan="1">29.0</td><td colspan="1" rowspan="1">357.4</td><td colspan="1" rowspan="1">393.0</td></tr><tr><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">146.7</td><td colspan="1" rowspan="1">190.3</td><td colspan="1" rowspan="1">463.1</td><td colspan="1" rowspan="1">440.5</td></tr><tr><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">181.2</td><td colspan="1" rowspan="1">150.3</td><td colspan="1" rowspan="1">382.2</td><td colspan="1" rowspan="1">376.7</td></tr><tr><td colspan="1" rowspan="1">70</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">Not Detected</td><td colspan="1" rowspan="1">545.7</td><td colspan="1" rowspan="1">445.7</td><td colspan="1" rowspan="1">480.2</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">10524.1</td><td colspan="1" rowspan="1">2549.1</td><td colspan="1" rowspan="1">2922.0</td></tr><tr><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">255.8</td><td colspan="1" rowspan="1">30.7</td><td colspan="1" rowspan="1">471.4</td><td colspan="1" rowspan="1">412.4</td></tr><tr><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">106.5</td><td colspan="1" rowspan="1">214.0</td><td colspan="1" rowspan="1">335.5</td><td colspan="1" rowspan="1">333.7</td></tr><tr><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">Not Detected</td><td colspan="1" rowspan="1">1769.8</td><td colspan="1" rowspan="1">501.3</td><td colspan="1" rowspan="1">483.9</td></tr><tr><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">Not Detected</td><td colspan="1" rowspan="1">706.1</td><td colspan="1" rowspan="1">657.9</td><td colspan="1" rowspan="1">609.1</td></tr><tr><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">Not Detected</td><td colspan="1" rowspan="1">5461.7</td><td colspan="1" rowspan="1">2014.2</td><td colspan="1" rowspan="1">2112.0</td></tr></table>

For Sample $\# 3 8$ , the hydrocodone concentration was $3 0 6 . 5 \mathrm { n g / m L }$ by LC-MS/MS and 307.0 $\mathrm { n g / m L }$ (positive) in semi-quantitative protocol and negative in the qualitative mode. The remaining 16 discordant samples all tested positive, greater than cutoff, by both ARK assay protocols. Cross-reactivity to the major metabolite hydromorphone contributed to the positive results for some of the samples with $< 3 0 0 ~ \mathrm { n g / m L }$ hydrocodone by LC-MS/MS.

2. Matrix Comparison: Not applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

# D Clinical Cut-Off:

Not applicable.

# E Expected Values/Reference Range:

Not applicable.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.